Chung-Han Lee, MD, PhD, discusses the most important factors in treatment selection for later-line therapy in renal cell carcinoma.
Chung-Han Lee, MD, PhD, assistant attending physician at Memorial Sloan Kettering Cancer Center, discusses the most important factors in treatment selection for later-line therapy in renal cell carcinoma (RCC).
Patients with advanced RCC generally receive a frontline tyrosine kinase inhibitor (TKI) plus immunotherapy or a dual immunotherapy combination. Later-line therapies include the options that were not used in the first line.
According to Lee, the outcome of frontline therapy can impact the choice of second and later-line therapy. Patients who respond well to a tyrosine kinase inhibitor (TKI) in the first line may also respond to other TKIs later on. Conversely, those who have significant toxicities related to a TKI may also be unable to tolerate a different TKI due to class-specific toxicities.
Patient performance is also significant since patients are most healthy and able to tolerate therapy in the first line. Tolerability becomes a greater concern when considering second- and third-line therapies due to a higher disease burden. Physicians may be challenged by the need to provide the most efficacy for patients while they also ensure that patients are able to maintain quality of life and safety during later-line treatment.
TRANSCRIPTION:
0:08 | When we talk about the second-line or later space in kidney cancer, the decision about what treatment choice to make—a lot of this is based off of how they responded in first line, and also the state of the patient after they've already progressed. For a patient who did very well with a TKI-based regimen in the first-line setting, our expectation is the effect of downstream TKIs may actually have very similar types of efficacy. For people who had a lot of toxicity to a first-line TKI, the expectation is that they may similarly experience a lot more toxicity than the typical patient to subsequent TKIs. This is based off of a class effect because most of the TKIs build upon targeting VEGF. Therefore, there are some class-specific toxicities that may result.
1:11 | The other part of it is really the patient aspect of it. Now, when we treat people in the first-line setting, it's often the case that in the first line, they are perhaps the most healthy that the patient may actually be. After they progress on first-line therapy, the overall disease burden is often higher than it was in [first-line] with subsequent lines of therapy, so their performance status may not necessarily be the same as in early lines. Therefore, we also have to take in consideration of the tolerability of various regimens and whether or not there would be good candidates for treatment that help balance that efficacy equation with the tolerability equation.
RELATIVITY-047 vs CheckMate 067 Matched Cohorts in Melanoma Show Similar Efficacy
October 10th 2024During a Case-Based Roundtable® event, Ahmad Tarhini, MD, PhD, discussed the indirect comparison of ipilimumab plus nivolumab and nivolumab/relatlimab in advanced melanoma in the second article of a 2-part series.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Long-Term Data Prompt Shifting Approaches to Frontline RCC Therapy
October 8th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of metastasis affect treatment of favorable-risk metastatic clear cell renal cell carcinoma in the second article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Later-Line CD19 and Bispecific Therapies Considered After CAR T
October 1st 2024During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to bispecific therapy use in diffuse large B-cell lymphoma in the second article of a 2-part series.
Read More
Five-Year Data Shows CheckMate 9LA Regimen Maintains Survival in NSCLC
September 24th 2024During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and chemotherapy for patients with non–small cell lung cancer in the first article of a 2-part series.
Read More